William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.
Nektar's (NKTR) rezpegaldesleukin demonstrates hair regrowth in alopecia areata patients but narrowly misses primary endpoint, presenting mixed results as company advances to Phase 3 trials.
A new medicine, rezpegaldesleukin, shows promise for moderate-to-severe eczema. It boosts special immune cells to rebalance the body and cut inflammation, leading to rapid and deeper symptom relief. It's an FDA Fast Tracked, self-injected treatment.
